BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8734285)

  • 21. Influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels.
    Rosario PW; Calsolari MR
    Thyroid; 2013 Jun; 23(6):671-4. PubMed ID: 23327335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.
    Saggiorato E; Rapa I; Garino F; Bussolati G; Orlandi F; Papotti M; Volante M
    J Mol Diagn; 2007 Apr; 9(2):214-9. PubMed ID: 17384213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin.
    Scheuba C; Kaserer K; Kotzmann H; Bieglmayer C; Niederle B; Vierhapper H
    Thyroid; 2000 May; 10(5):413-6. PubMed ID: 10884188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathology of C Cells and Medullary Thyroid Carcinoma.
    Schmid KW
    Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1.
    Segni M; Massa R; Bonifacio V; Tartaglia F; Pucarelli I; Marzullo A; Pasquino AM
    Horm Res; 2001; 56(1-2):63-6. PubMed ID: 11815730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma.
    Cascon A; Cebrian A; Pollan M; Ruiz-Llorente S; Montero-Conde C; Leton R; Gutierrez R; Lesueur F; Milne RL; Gonzalez-Albarran O; Lucas-Morante T; Benitez J; Ponder BA; Robledo M
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2127-30. PubMed ID: 15623805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.
    Barbot N; Calmettes C; Schuffenecker I; Saint-André JP; Franc B; Rohmer V; Jallet P; Bigorgne JC
    J Clin Endocrinol Metab; 1994 Jan; 78(1):114-20. PubMed ID: 7904611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene.
    Foppiani L; Forzano F; Ceccherini I; Bruno W; Ghiorzo P; Caroli F; Quilici P; Bandelloni R; Arlandini A; Sartini G; Cabria M; Del Monte P
    Eur J Endocrinol; 2008 Mar; 158(3):417-22. PubMed ID: 18299477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma.
    Kwon H; Kim WG; Choi YM; Jang EK; Jeon MJ; Song DE; Baek JH; Ryu JS; Hong SJ; Kim TY; Kim WB; Shong YK
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):598-603. PubMed ID: 25041034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism.
    Zou S; McDow AD; Saeed Z; Hou T
    Cureus; 2023 Jan; 15(1):e33384. PubMed ID: 36751230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of calcitonin-containing parafollicular cells of the thyroid in patients with chronic lymphocytic thyroiditis: a clinical, pathological and immunohistochemical study.
    Lukács G; Sápy Z; Gyóry F; Tóth V; Balázs G
    Acta Chir Hung; 1997; 36(1-4):204-6. PubMed ID: 9408347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [How to interprete hypercalcitoninemia?].
    Levy-Bohbot N; Patey M; Larbre H; Hecart AC; Caron J; Delemer B
    Rev Med Interne; 2006 Aug; 27(8):610-5. PubMed ID: 16857299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
    Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
    Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrastructure in C cell hyperplasia in asymptomatic patients with hypercalcitoninemia and a family history of medullary thyroid carcinoma.
    Asaadi AA
    Hum Pathol; 1981 Jul; 12(7):617-22. PubMed ID: 7275099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcitonin and histaminase in C-cell hyperplasia and medullary thyroid carcinoma. A light microscopic and immunohistochemical study.
    Mendelsohn G; Eggleston JC; Weisburger WR; Gann DS; Baylin SB
    Am J Pathol; 1978 Jul; 92(1):35-52. PubMed ID: 99045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis.
    Biddinger PW; Brennan MF; Rosen PP
    Am J Surg Pathol; 1991 Jun; 15(6):599-604. PubMed ID: 1674409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
    Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proliferative activity in C-cell hyperplasia and medullary thyroid carcinoma. Evaluation by PCNA immunohistochemistry and AgNORs staining.
    Matias-Guiu X; Peiro G; Esquius J; Oliva E; Cabezas R; Colomer A; Prat J
    Pathol Res Pract; 1995 Feb; 191(1):42-7. PubMed ID: 7651932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.